InsidersTradesSigma
Cryoport, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Cryoport, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Industry sector, Cryoport, Inc. has recorded 72 public disclosures. Market capitalisation: €662.3m. The latest transaction was reported on 22 July 2025 (Levée d'options). Among the most active insiders: SHELTON JERRELL. All data is accessible without an account.
72
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€979,113
22 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Cryoport, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$14.56.
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 2,426 of 25,791 companies
74.3
score / 100
Value88
Quality61
FCF yld·
Earn yld10%
EV/EBITDA·
ROE-8.2%
Gross mgn47%
Net mgn44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 July 2025
Declarations72 total
25,000 shares@ US$5.006.3% of flowCommon StockSEC:0001104659-25-069643:0
23,214 shares0Common StockSEC:0001104659-25-058266:0
12,500 shares@ US$6.1029.6% of flowCommon StockSEC:0001104659-25-055047:0
1,349 shares@ US$6.941612.5% of flowCommon StockSEC:0001104659-25-028324:0
2,980 shares@ US$6.94161.1% of flowCommon StockSEC:0001104659-25-028320:0
1,070 shares@ US$6.94161.7% of flowCommon StockSEC:0001104659-25-028322:0
9,000 shares0Common StockSEC:0001104659-25-025193:0
30,000 shares0Common StockSEC:0001104659-25-025192:0
10,000 shares0Common StockSEC:0001104659-25-025194:0
8,000 shares0Common StockSEC:0001104659-25-025196:0
2,667 shares0Common StockSEC:0001104659-25-022642:0
2,667 shares0Common StockSEC:0001104659-25-022644:0
8,250 shares0Common StockSEC:0001104659-25-022643:0
53,334 shares@ US$4.8062.0% of flowCommon StockSEC:0001104659-24-128537:0
10,834 shares@ US$4.8044.8% of flowCommon StockSEC:0001104659-24-125631:0
2,500 shares@ US$6.486.7% of flowCommon StockSEC:0001104659-24-124748:0
59,150 shares@ US$4.8015.8% of flowCommon StockSEC:0001104659-24-122676:0
60,215 shares@ US$4.8016.1% of flowCommon StockSEC:0001104659-24-121156:0
1,000 shares@ US$9.4653.7% of flowCommon StockSEC:0001104659-24-092969:0
1,000 shares@ US$8.39543.3% of flowCommon StockSEC:0001104659-24-091339:0
4,167 shares@ US$5.0417.7% of flowCommon StockSEC:0001104659-24-086387:0
12,845 shares0Common StockSEC:0001104659-24-063966:0
12,845 shares0Common StockSEC:0001104659-24-063964:0
12,845 shares0Common StockSEC:0001104659-24-063968:0
12,845 shares0Common StockSEC:0001104659-24-063961:0
25 of 72 declarations
About Cryoport, Inc.
Cryoport, Inc. (NASDAQ: CYRX) is a specialized life sciences supply-chain company headquartered in Brentwood, Tennessee, United States. Founded in 1999, it has evolved from a logistics-focused business into an integrated platform serving biopharmaceutical, animal health, and human reproductive medicine markets. For investors, Cryoport should be viewed less as a traditional transporter and more as mission-critical infrastructure for temperature-sensitive and high-value biological products. The company’s core business centers on temperature-controlled logistics, cryogenic and ultra-cold shipping systems, bio-storage, and related services for advanced therapies. Its platform supports cell and gene therapy developers, biologics manufacturers, clinical trial programs, and other sensitive life-science applications. Over time, Cryoport has broadened its offering beyond shipping into cryopreservation, biostorage, packaging, labeling, kit production, and logistics orchestration. That broader scope increases wallet share and makes the company more embedded in customer workflows. Cryoport’s competitive positioning is built on specialization, compliance, and operational reliability. In advanced therapies, where product integrity and chain-of-custody are essential, the company’s expertise in regulated, temperature-controlled supply chains creates meaningful barriers to entry. Its value proposition is tied to reducing risk for customers running complex global programs, especially in cell and gene therapy, where a logistics failure can destroy a high-value batch. The group emphasizes its global reach across the Americas, EMEA, and APAC, with more than 50 strategic locations and a customer base exceeding 3,000 worldwide. Recent developments underline the company’s strategic expansion. In June 2024, Cryoport officially launched its Global Supply Chain Hub in Stevenage, U.K., strengthening its European footprint. In January 2025, it announced a strategic partnership with Moffitt Cancer Center to establish a state-of-the-art biorepository center in Florida. Its 2024 annual report also showed continued traction in its core market, with 701 clinical trials supported globally at year-end 2024, including 81 phase 3 trials. More broadly, Cryoport remains a growth-oriented platform leveraged to the expansion of advanced therapies, but its investment case depends on execution, commercial adoption in cell and gene therapy, and the company’s ability to translate its international footprint into durable profitability.
